⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Randomized Study Comparing the Effect of Dasatinib and Imatinib on Malignant Stem Cells in Chronic Myeloid Leukemia

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Randomized Study Comparing the Effect of Dasatinib and Imatinib on Malignant Stem Cells in Chronic Myeloid Leukemia

Official Title: An Open-Label, Randomized, Multicenter Phase II Trial Comparing the Depletion of Malignant Stem Cells With Dasatinib vs. Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid

Study ID: NCT00852566

Interventions

Imatinib
Dasatinib

Study Description

Brief Summary: A randomized multi-center study comparing the effect of dasatinib and imatinib on malignant stem cells in newly diagnosed chronic phase chronic myeloid leukemia (CML) patients. The research hypothesis is that treatment with dasatinib 100 mg daily (QD) results in greater and more rapid depletion of the Philadelphia (Ph) -positive stem cell pool within 6 months of therapy than imatinib 400 mg QD in newly diagnosed CML patients. The study duration is 18 months and approximately 40 patients will be recruited to the study.

Detailed Description: An Open-Label, Randomized, Multicenter Phase II Trial Comparing the depletion of malignant stem cells with Dasatinib vs. Imatinib in Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Estimated Number of Study Centers and Countries/Regions: Appr. 12 sites in 5 Nordic countries. Stem cell analyses will be performed in 4 Nordic centers (Helsinki, Lund, Oslo and Stockholm). Study Phase: II Research Hypothesis: Treatment with dasatinib 100 mg daily (QD) results in greater and more rapid depletion of the Philadelphia (Ph) -positive stem cell pool within 6 months of therapy than imatinib 400 mg QD in newly diagnosed chronic phase (CP) chronic myeloid leukemia (CML) patients. Primary Objective: To compare the number of Ph-positive cells in the stem cell compartment in newly diagnosed CP CML patients treated with dasatinib 100 mg QD vs. imatinib 400 mg QD. Study Design: open-label randomized Phase II trial in newly diagnosed CML patients in CP. Patients will be randomized to receive dasatinib at a starting dose of 100 mg QD or imatinib at a starting dose of 400 mg QD. Duration of Study: The study will be open for enrollment until the planned number of 40 patients is randomized. All patients will be treated and/or followed for up to 18 months. Based on the amendment 1 (Oct 2011), the follow-up of the patients will continue additional 4 years until 31.12.2015. Number of Patients per Group: Approximately 40 patients will be randomized, 20 patients to dasatinib and 20 to imatinib. Additional patients will be recruited in case insufficient amount of representative samples have been obtained from first 40 patients. Study Population: Patients 18 years or older with a newly diagnosed CP CML, not previously treated with any systemic treatments for CML Study Assessments and Endpoints: All stem cell assays are based on the preselection of CD34+ cells from large volume of bone marrow (BM) aspirates using paramagnetic beads. The CD34+ fraction will be further subdivided based on the expression of CD38 marker (positive vs. negative) using a sorting flow cytometer. The primary endpoint is a comparison of proportion of Ph-positive cells in stem cell compartments (CD34+CD38neg and CD34+CD38+) at 6 months between the study arms. Secondary endpoints are comparisons between treatment arms for: (1) the number of Ph-positive cells in all stem cell compartments at 1 and 3 months, (2) BCR-ABL RQ-PCR in blood at 1, 3, 6, 12 and 18 months, and (3) rate of CCyR within 3, 6, 12 and 18 months.

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Helsinki University Central Hospital, Helsinki, , Finland

Bergen University Central Hospital, Bergen, , Norway

Rikshospitalet, Oslo, , Norway

St. Olavs Hospital, Trondheim, , Norway

Lund University Hospital, Lund, , Sweden

Karolinska University Hospital, Stockholm, , Sweden

Uppsala University Hospital, Uppsala, , Sweden

Contact Details

Name: Satu Mustjoki, MD, PhD

Affiliation: Helsinki University Central Hospital, helsinki, Finland

Role: PRINCIPAL_INVESTIGATOR

Name: Henrik Hjorth-Hansen, MD, PhD

Affiliation: St. Olavs Hospital, Trondheim, Norway

Role: STUDY_CHAIR

Name: Ole Weiss-Bjerrum, MD, PhD

Affiliation: Rigshospitalet, Denmark

Role: STUDY_CHAIR

Name: Ingunn Dybedal, MD, PhD

Affiliation: Rikshospitalet, Oslo, Norway

Role: STUDY_CHAIR

Name: Tobias Gedde-Dahl, MD, PhD

Affiliation: Rikshospitalet, Oslo, Norway

Role: STUDY_CHAIR

Name: Kimmo Porkka, MD, PhD

Affiliation: Helsinki University Central Hospital, Helsinki, Finland

Role: STUDY_CHAIR

Name: Johan Richter, MD, PhD

Affiliation: University of Lund, Lund, Sweden

Role: STUDY_CHAIR

Name: Bengt Simonsson, MD, PhD

Affiliation: University Hospital, Uppsala, Sweden

Role: STUDY_CHAIR

Name: Leif Stenke, MD, PhD

Affiliation: Karolinska Institutet

Role: STUDY_CHAIR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: